Hanmi Pharm. Co., Ltd. (128940.KS)
- Previous Close
277,000.00 - Open
274,000.00 - Bid 288,500.00 x --
- Ask 289,000.00 x --
- Day's Range
272,000.00 - 293,500.00 - 52 Week Range
214,500.00 - 375,000.00 - Volume
146,453 - Avg. Volume
67,920 - Market Cap (intraday)
3.658T - Beta (5Y Monthly) 0.64
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date Jul 28, 2025 - Aug 1, 2025
- Forward Dividend & Yield 1,250.00 (0.45%)
- Ex-Dividend Date Dec 27, 2024
- 1y Target Est
353,500.00
Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company's products include Gugutams, a urological combination therapy combining two active ingredients: tamsulosin, a treatment for Obstructive Prostatic Growth (OPG), and tadalafil, a treatment for erectile dysfunction (ED). The company has a research collaboration with MEDIC Life Sciences Inc. to identify cancer biomarkers. The company was founded in 1973 and is based in Hwaseong-si, South Korea.
www.hanmipharm.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 128940.KS
View MorePerformance Overview: 128940.KS
Trailing total returns as of 5/14/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 128940.KS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 128940.KS
View MoreValuation Measures
Market Cap
3.51T
Enterprise Value
3.82T
Trailing P/E
28.95
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.35
Price/Book (mrq)
3.24
Enterprise Value/Revenue
2.55
Enterprise Value/EBITDA
13.03
Financial Highlights
Profitability and Income Statement
Profit Margin
8.11%
Return on Assets (ttm)
6.78%
Return on Equity (ttm)
12.00%
Revenue (ttm)
1.5T
Net Income Avi to Common (ttm)
121.32B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
193.2B
Total Debt/Equity (mrq)
40.03%
Levered Free Cash Flow (ttm)
132.23B